Skip to main content

Advertisement

Table 2 Univariate and multivariate analyses for PFS

From: Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts

Variable (comparator) Progression free survival
Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
BMI (< 25 vs ≥ 25) 1.71 (1.09–2.67) 0.0182 1.73 (1.09–2.74) 0.0184
Primary tumor (NSCLC)
 Melanoma 0.53 (0.29–0.99) 0.0463 0.48 (0.26–0.91) 0.0236
 Kidney 0.75 (0.39–1.43) 0.3880 0.59 (0.31–1.48) 0.1223
 Others 0.77 (0.27–2.13) 0.6191 0.80 (0.28–2.23) 0.6715
Sex (Male vs Female) 1.23 (0.76–1.99) 0.3881 1.15 (0.71–1.87) 0.5734
Age (Elderly vs Non-elderly) 1.04 (0.66–1.61) 0.8570
Treatment line (Non-first vs First) 1.72 (0.96–3.06) 0.0639
Burden of disease (> 2 vs ≤ 2 sites) 1.20 (0.75–1.92) 0.4295
ECOG PS (≥ 2 vs 0–1) 2.29 (1.86–4.70) < 0.0001 2.94 (1.84–4.69) < 0.0001